Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00025506 · BASELINE

Baseline characteristics

Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus · Source last updated 2019-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      45
    units
    Participants
groups
  1. description
    Thalidomide 200 mg PO once a day initial dose (each 28-day period will be considered one cycle). Dose increased by 200 mg every 2 weeks to maximum dose of 1000 mg/day until disease progression or adverse effects prohibit further therapy.
    id
    BG000
    title
    Thalidomide
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          8.9
          value
          65.6
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      30-39 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      40-49 years
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          7
      title
      50-59 years
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          23
      title
      60-69 years
    5. categories
      1. measurements
        1. group Id
          BG000
          value
          11
      title
      70-79 years
    6. categories
      1. measurements
        1. group Id
          BG000
          value
          2
      title
      80-89 years
    param Type
    NUMBER
    title
    Age, Customized
    unit Of Measure
    participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          45
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          0
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          45
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
  5. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          22
      title
      Carcinosarcoma-homologous
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          16
      title
      Carcinosarcoma-heterologous
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          7
      title
      Carcinosarcoma, MMT
    param Type
    NUMBER
    title
    Histologic type
    unit Of Measure
    participants
population Description
Eligible and treated patients.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      45
    units
    Participants
groups
  1. description
    Thalidomide 200 mg PO once a day initial dose (each 28-day period will be considered one cycle). Dose increased by 200 mg every 2 weeks to maximum dose of 1000 mg/day until disease progression or adverse effects prohibit further therapy.
    id
    BG000
    title
    Thalidomide
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          8.9
          value
          65.6
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      30-39 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      40-49 years
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          7
      title
      50-59 years
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          23
      title
      60-69 years
    5. categories
      1. measurements
        1. group Id
          BG000
          value
          11
      title
      70-79 years
    6. categories
      1. measurements
        1. group Id
          BG000
          value
          2
      title
      80-89 years
    param Type
    NUMBER
    title
    Age, Customized
    unit Of Measure
    participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          45
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          0
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          45
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
  5. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          22
      title
      Carcinosarcoma-homologous
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          16
      title
      Carcinosarcoma-heterologous
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          7
      title
      Carcinosarcoma, MMT
    param Type
    NUMBER
    title
    Histologic type
    unit Of Measure
    participants
population Description
Eligible and treated patients.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice